Menu Close

Newly approved oncology patent for First Health Pharma

Our new oncology patent WO2022180080 was approved and is already available in the WIPO database. The patent protects a new generation of antitumor agents with high activity, low toxicity and a favorable pharmacological profile. FHP continues its work on clinical candidates with its improved generations of patented compounds, active against important targets such as Lung Cancer, Triple Negative Breast Cancer and Liver Cancer.

Wake up and Kill HIV

HIV reservoir reduction

Since the publication of our Reservoir Reducing results by our partners of the Erasmus Medical Center in Nature Communications last year, several new studies by our academic partners in the Netherlands and Italy confirm these results in different assays. The Nature paper discusses a 50% reduction of the inducible HIV reservoir after a five-day treatment with our DDX3 RNA helicase inhibitor in blood of people living with HIV (PLWHIV). This ex-vivo experiment was carried out without the added use of a latency reversing agent (LRA) making it the first ever published result of HIV reservoir reduction through “shock and kill”…

In memory of Mickey Huibregtsen

It is with great sadness that we have to communicate the death of our dear friend and co-founder of First Health Pharmaceuticals, F. Wouter (Mickey) Huibregtsen. Mickey had a long and successful business career as managing director of McKinsey & Company in Amsterdam but his many contributions to society were his major driving force in life. Mickey was head of the Dutch Olympic Committee and founder of several charities and NGO’s. The annual Huibregtsen award for scientific excellence in the Netherlands was named after him. Mickey was also a co-founder and chairman of the First Health United Foundation and the…

DISCLAIMER: Fraud Recruitment Offers

disclaimer recruitment fraud

  DISCLAIMER: Fraud Recruitment Offers ! Please be aware of a job scam circulating on behalf of First Health Pharmaceuticals B.V. Don’t apply to any home working opportunities from First Health Pharmaceuticals B.V. Don’t click on any Telegram account link from First Health Pharmaceuticals B.V. ! It has come to our notice that fake job offers are being circulated on behalf of First Health Pharmaceuticals B.V. by certain individuals/entities claiming they are HR representatives of First Health Pharmaceuticals B.V. PLEASE NOTE THAT: –The domain of First Health Pharmaceuticals B.V. is firsthealthpharma.com and NOT firsthealthpharm.com -The contact email of First Health…

First Health Pharmaceuticals DDX3X RNA Helicase Inhibitor compound proved successful as an Anti-Tumor agent in Breast Cancer

breast cancer

A study led by First Health Pharmaceuticals B.V. (FHPBV) and the Italian Institute of oncological research and prevention (ISPRO), together with the University of Siena and the Italian National Research Center (CNR) focused on assessing the antitumor activity of the FHP01 DDX3X helicase inhibitor compound developed by First Health Pharmaceuticals in in vivo breast cancer preclinical models. FHP01 proved to be highly active against different breast cancer cell types, including triple-negative breast cancer (TNBC) models. Most importantly, the study showed that this small molecule drug candidate works effectively as a standalone treatment rather than in a combination therapy. Read the…

Breakthrough achievements in HIV Cure

Today, the prestigious scientific journal Nature Communications published the article “Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir”. The article reports on groundbreaking research performed by Dr. Shringar Rao PhD and Prof. Dr. Tokameh Mahmoudi PhD and their research group of the Erasmus Medical Center of Rotterdam (EMC). Dr. Rao and Dr. Mahmoudi investigated specific mechanisms of reduction of the latent HIV reservoir by means of DDX3 inhibiting compounds. We refer to the publication itself for further details on their research. One of the DDX3 inhibiting antiviral compounds that was used in the…

New lab facilities in Italy to expand on our existing R&D

new laboratory in Colle di Val d’Elsa

Besides our Research and Development in The Netherlands, First Health Pharmaceuticals has important collaborations worldwide, especially in countries such as India and Italy. Recently we opened new laboratory facilities in Colle di Val d’Elsa – Italy, where we concentrate several of our local R&D units under one roof and will also operate as a hub for our partners in the life sciences concentration around Siena. Our new lab is equipped with proprietary state of the art instruments, such as the latest spectrometers, advanced automated plate readers and cell counting equipment. Our new Italian laboratory hosts four principal development units: Biology,…

WORLD AIDS DAY 2020

World AIDS Day occurring each December 1, helps reminding civil society and governments every year that HIV is still relevant. Its awareness-raising mission includes activities that take place around the globe to highlight the current state of epidemic and trace the path of its eradication. EXTRAORDINARY TIMES CALL FOR EXTRAORDINARY ACTIONS This year ’s specific theme couldn’t not take into account the CoViD-19 pandemic and its impact on HIV and AIDS. We must not neglect the fact that the Covid-19 pandemic already had and still has a negative effect not only on cancer and other major diseases, but also on the HIV/AIDS epidemic,…

Interference with RNA metabolism as a means to fight CoViD19

First Health Pharmaceuticals has been investigating the activity of its compounds on the replication of various RNA viruses, therefore, no wonder that we have also successfully tested in vitro models of SAR-COV2 infection. Currently we have undertaken projects with leading clinical centers for COVID19 research and treatment in the Netherlands where the compounds are going to be tested in patient samples. Besides assessing the activity on the replication of the virus, First Health Pharma is also committed to assess the anti-inflammatory component of the compounds which represents an important added value to counteract the more frequent comorbidity and cause of…

First Health Pharma announces participation in a new CoViD-19 research project in the Netherlands

Clinically-validated nasal airway epithelial cell models for COVID-19 high throughput drug development As the unparalleled global health crises caused by the novel coronavirus SARS-CoV-2 seems not to have come to an end, the continuous research efforts for CoViD-19 antivirals and vaccine remain the only hope for the light at the end of the tunnel. Since the beginning of the pandemic, First Health Pharmaceuticals has extended its commitment to the finding of a cure for CoViD-19 also, alongside its main research focus on HIV and other RNA viruses and cancer. This commitment includes its participation in a collaborative project led by…